Humuline 30/70 Cartridge (Insulin Human (Rdna))

Humuline 30/70 Cartridge is indicated for the management of blood glucose in adults with diabetes mellitus.

• Type 1 diabetes mellitus as part of a basal‑bolus insulin regimen.
• Type 2 diabetes mellitus when oral agents and lifestyle measures do not achieve target glycaemia.
• Adjunct therapy during periods of increased insulin demand, such as illness or surgery.
• Use in combination with rapid‑acting insulin analogues for flexible mealtime coverage.
• Pediatric patients with type 1 diabetes when weight‑based dosing is appropriate.
• Patients requiring a fixed proportion of rapid and intermediate insulin to simplify dosing schedules.

• Humuline 30/70 contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose production. The 30/70 ratio provides an initial rapid‑acting component followed by a prolonged intermediate effect.

Adverse reactions to Humuline 30/70 may occur; they are categorized by frequency and clinical significance.

Common

• Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy presenting as localized thickening or loss of subcutaneous fat at repeated injection sites.
• Weight gain associated with increased insulin dosing.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness).
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or heart failure exacerbation in susceptible patients.
• Hypersensitivity leading to serum sickness–like reaction.

When prescribing or using Humuline 30/70, clinicians and patients should consider several precautionary measures to minimize risk.

• Adjust dose during reduced food intake, increased activity, or illness to avoid hypoglycemia.
• Monitor blood glucose frequently when initiating therapy or changing insulin‑to‑carbohydrate ratios.
• Use caution in renal or hepatic impairment because insulin clearance may be decreased.
• Assess for cardiovascular disease; rapid fluid shifts can worsen heart failure.
• Avoid use in patients with known hypersensitivity to human insulin or cartridge components.

Humuline 30/70 may interact with other medications; understanding these interactions helps maintain glycemic control and safety.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment, which can cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, potentially delaying treatment.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase insulin secretion, requiring careful glucose monitoring.
• Corticosteroids, thiazide diuretics, or sympathomimetics that raise blood glucose, possibly necessitating higher insulin doses.
• Alcohol intake, especially in excess, which can cause unpredictable glucose fluctuations.